Status:

COMPLETED

A Phase I Study of Safety and Pharmacokinetics of Nevirapine in HIV-1 Infected Pregnant Women and Neonates Born to HIV-1 Infected Mothers

Lead Sponsor:

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions:

HIV Infections

Pregnancy

Eligibility:

FEMALE

13-60 years

Phase:

PHASE1

Brief Summary

To determine the bioavailability, pharmacokinetics, and short-term safety and tolerance of nevirapine in HIV-1 infected pregnant women and their newborns when nevirapine is given to the mother during ...

Detailed Description

Treatment of HIV-1 infected pregnant women during active labor may result in therapeutic levels of nevirapine in the neonate at the time of exposure to HIV-1 during parturition, decreasing the neonate...

Eligibility Criteria

Inclusion Criteria

Concurrent Medication:

Allowed:

  • AZT (mothers and neonates).
  • Oral asthma inhalers (mothers).

Concurrent Treatment:

Allowed:

  • Phototherapy (neonates).

MOTHERS must have:

  • HIV infection.
  • Estimated gestational age >= 34 weeks.
  • No active opportunistic infection at study entry.

PER AMENDMENT 8/27/96:

  • A pre-enrollment plasma HIV-1 RNA level greater than 10,000 copies/ml.

Exclusion Criteria

Co-existing Condition:

MOTHERS with the following symptoms or conditions are excluded:

  • Intrauterine growth retardation.
  • Fetal anomaly incompatible with life as determined by pre-entry ultrasound.
  • Participation during current pregnancy in any other therapeutic or vaccine perinatal trial.
  • Known hypersensitivity to any benzodiazepine.
  • Serious bacterial infection.

Concurrent Medication:

Excluded:

  • Any antiretroviral other than AZT.
  • Corticosteroids (other than oral asthma inhalers).
  • Anticoagulants.
  • Any clavulanic acid-containing formulation (e.g., Augmentin, Timentin).
  • Benzodiazepines other than study drug.
  • Phenobarbital.
  • Barbiturates.
  • Antacids.
  • Magnesium sulfate.

Prior Medication:

Excluded:

  • Prior nevirapine.

Current use of illicit substances and/or active chronic alcohol use.

Key Trial Info

Start Date :

Trial Type :

INTERVENTIONAL

End Date :

September 1 1998

Estimated Enrollment :

49 Patients enrolled

Trial Details

Trial ID

NCT00000808

End Date

September 1 1998

Last Update

November 4 2021

Active Locations (16)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (16 locations)

1

UCSD Med Ctr / Pediatrics / Clinical Sciences

La Jolla, California, United States, 920930672

2

Los Angeles County - USC Med Ctr

Los Angeles, California, United States, 90033

3

UCLA Med Ctr / Pediatric

Los Angeles, California, United States, 900951752

4

Harbor - UCLA Med Ctr / UCLA School of Medicine

Los Angeles, California, United States, 905022004

A Phase I Study of Safety and Pharmacokinetics of Nevirapine in HIV-1 Infected Pregnant Women and Neonates Born to HIV-1 Infected Mothers | DecenTrialz